At the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), Caris Life Sciences revealed more positive results from studies using their Caris Molecular Intelligence™ technology. During the meeting, Fadi Braiteh, MD, from Comprehensive Cancer Centers of Nevada and US Oncology Research, presented a poster detailing the molecular profiles of various types of gastrointestinal cancer and potential drug options for patients.
Earlier in the year, Caris presented data at the 2014 Gastrointestinal Cancers Symposium, and this current work adds to the repertoire of using Caris Molecular Intelligence for gastrointestinal cancers. Clinical data from nine total studies were presented. Notably, the studies included more than 14,000 cases of of 17 different types of gastrointestinal cancer, as well as a subset of nearly 7,000 colorectal cancer patients, all with the intention of opening new treatment options to patients.
“This study, with its large, diverse patient population, including a very large number of patients from the community setting, demonstrates how molecular profiling can be utilized beyond just the university centers, and offers a potential new way to classify gastrointestinal cancers based on the underlying molecular aberrations instead of by organ and tissue of origin,” said Dr. Braiteh in a news release from Caris, regarding the study of 14,207 patients. Up to 70 molecular abnormalities were found in tumor samples. Highlights of the findings include Her2 overexpression, KRAS mutations, PTEN loss of expression, and cMET overexpression in combinations unique to certain subsets of cancers.
“Our analysis showed that cancers from different gastrointestinal subtypes may share the same molecular pathway, suggesting that the same types of targeted therapy may be appropriate across gastrointestinal cancer subtypes, while other types of therapies – whether standard of care or investigational – may be better suited for cancers with more distinct molecular profiles,” concluded Dr. Braiteh.
The other study of 6,892 tumor samples was conducted in conjunction with Penn State Hershey Cancer Institute and was presented by Wafik El-Deiry, MD, PhD and FACP. Highlights from the seven different metastatic tumor sites include Her2 overexpression, Top2A amplification, KRAS mutations, and TOPO1 overexpression in certain metastases that both suggest and eliminate treatment options for patients.
“Whereas KRAS and BRAF mutations can make colorectal cancer especially aggressive, patients with these mutations have long been thought to have limited treatment options, and there are no detailed treatment guidelines that specifically address various sites of metastasis,” explained Dr. El-Deiry. “We identified significant differences among tumors with these mutations, as well as at the different sites of metastasis, providing support for selecting treatments that, in many cases, have not traditionally been considered for patients with colorectal cancer.”
Driving home the power of Caris Molecular Intelligence, Sandeep Reddy, MD, Chief Medical Officer at Caris stated, “Our comprehensive, multiplatform approach to molecular profiling is helping oncologists individualize treatment regimens according to the molecular signature of a patient’s tumor. This year’s ASCO presentations by Caris include posters demonstrating how biomarker analysis can inform treatment guidelines and therapeutic decision-making for patients with various types of gastrointestinal cancer, including those of the colon and rectum, stomach, esophagus, bile duct and gallbladder. Given the substantial breadth and depth of these gastrointestinal studies, we believe these findings should stimulate serious discussion and wider adoption of molecular profiling techniques by the broader oncology community.”
Seventeen percent of all new cancer cases in the United States are malignancies of the digestive system, and these account for more than 25% of cancer-related deaths.